Neurology

AMX0035 lower long-term risk of death in ALS

Patients with amyotrophic lateral sclerosis (ALS) randomized to receive AMX0035 (Amylyx Pharmaceuticals, Inc) had significantly lower long-term risk of death or permanent assisted ventilation (PAV) and risk of first hospitalization compared to patients treated with placebo, according to a company press release. “We are strongly encouraged by the results from...